The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.

Tirzepatide includes blockbuster injected GLP-1 medications Mounjaro (for diabetes) and Zepbound (for weight loss).

Results from the VENTURE trial showed significant reductions in weight and hunger among younger patients treated with ...

The single-use product is surgically implanted for arterial replacement and repair after a traumatic injury to the extremity.

CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist.

The Food and Drug Administration (FDA) has approved Tryngolza™ (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).

Zealand Pharma expects to start a single phase 3 trial in 2025 to provide confirmatory data for resubmission. The Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to ...

The investigational therapy combines doravirine, a non-nucleoside reverse transcriptase inhibitor, with islatravir, a nucleoside reverse transcriptase translocation inhibitor.

The Food and Drug Administration (FDA) has approved Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft vs host disease (SR-aGvHD) in pediatric patients 2 months of age ...

(HealthDay News) — Transcutaneous auricular vagus nerve stimulation (taVNS) reduces insomnia severity, according to a study published online Dec. 16 in JAMA Network Open.

(HealthDay News) — In a case first reported in Louisiana last Friday, a patient has now developed the first known case of bird flu so severe as to require hospitalization, according to the US Centers ...

No association seen for increased risks for dementia, cognitive impairment without dementia, accelerated cognitive decline ...